Discontinuation report LORAZEPAM INJECTION USP
Report ID | 106265 |
Drug Identification Number | 02438704 |
Brand name | LORAZEPAM INJECTION USP |
Common or Proper name | LORAZEPAM |
Company Name | SANDOZ CANADA INCORPORATED |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | LORAZEPAM |
Strength(s) | 2MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAMUSCULAR INTRAVENOUS |
Packaging size | 1ml x 1 vial |
ATC code | N05BA |
ATC description | ANXIOLYTICS |
Reason for discontinuation | Other (Please describe in comments) |
Anticipated discontinuation date | |
Actual discontinuation date | 2020-02-14 |
Remaining supply date | 2020-12-31 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | unforeseeable supply issue |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2020-03-12 | French | Compare |
v5 | 2020-03-12 | English | Compare |
v4 | 2020-02-15 | French | Compare |
v3 | 2020-02-15 | English | Compare |
v2 | 2020-02-14 | English | Compare |
v1 | 2020-02-14 | English | Compare |
Showing 1 to 6 of 6